



## Structured Administration and Supply Agreement Administration of *Bacillus Calmette-Guérin (BCG) vaccine*

### SASA Details

Title:	<i>Bacillus Calmette-Guérin (BCG) vaccine administration for Registered Nurses working within the WACHS</i>
Identifying Number:	<i>2024-ED-CO-24-511386</i>

### Issuing Authority

HSP Name:	<i>WACHS CEO under section 6 Medicine and Poisons Regulations 2016</i>
Address:	<i>189 Wellington Street, PERTH 6000</i>
Contact:	<i>9223 8525</i>

### Authorised Persons

Practitioners:	<i>Registered Nurses working within WACHS</i>
Location:	<i>When employed by, or contracted to provide services to WACHS</i>
Qualification:	<i>Registered Nurses who have</i> <ul style="list-style-type: none"><li><i>Registered with Australian Health Practitioner Regulation Agency</i></li><li><i>completed the current approved WA Health immunisation course 'Understanding vaccines and the national immunisation program' (<a href="#">on-line</a>).</i></li><li><i>completed the Tuberculin Skin Test (TST) training and have been deemed competent in administration of TST,</i></li><li><i>completed the 'WATPCP Practical BCG Training' and have been deemed competent to deliver intradermal injection of BCG vaccine by an authorised assessor,</i></li><li><i>Undertaken a review of the WATBCP 'BCG Training Presentation PowerPoint'.</i></li><li><i>To maintain competency staff will be required to provide proof of administration of at least 5 BCG vaccines within a 12-month period or current competency certification by a WACHS authorised assessor.</i></li><li><i>Undertake annual immunisation updates as specified by WA Health.</i></li></ul>

<b>Authorised Medicine</b>			
Medicine Name:	<i>Bacillus Calmette-Guérin (BCG) Anti-Tuberculosis Vaccine</i>	Brand:	<i>Mycobacterium bovis Bacille Calmette-Guérin (BCG) Statens Serum Institute (SSI) Danish strain 1331, live attenuated</i>
Form:	<i>Powder for suspension for injection, reconstitute with 1.0 mL Diluted Sauton AJV</i>	Strength:	<i>1mL reconstituted contains 2 to 8 million Colony Forming Units (cfu)</i>
Dose:	<ul style="list-style-type: none"> <li><i>Infants under 12 months of age: 0.05 mL</i></li> <li><i>Adults and children aged 12 months and older: 0.1mL</i></li> </ul>	Quantity:	<i>Once only</i>
Route:	<i>Intradermal Injection</i>		
Instructions:	<i>Administer required dose according to age as a single intradermal vaccination after reconstitution with diluent according to manufacturer's instruction</i>		

<b>Approved Circumstances</b>	
Authorised to:	<i>Administer Bacillus Calmette-Guérin (BCG) vaccine to reduce the likelihood of Tuberculosis infection progressing to disease for a specific cohort of children and to offer protection against leprosy among contacts of leprosy</i>
Place:	<i>Registered Nurses working within WACHS who have completed the training as outlined and deemed competent to deliver intradermal injections</i>
Patients:	<i>Patients who meet the inclusion criteria for BCG vaccination</i>
Medical Condition:	<i>N/A</i>

<b>Clinical / Other Information</b>	
Patient Inclusion:	<p><i>As indicated in the WATBCP WA Tuberculosis Guideline:</i></p> <ul style="list-style-type: none"> <li><i>Children less than 6 years of age who are going to live in a country with high Tuberculosis incidence (annual incidence of &gt; 40 / 100 000 population) for more than 3 months (once off or cumulatively). BCG should be given 2 – 3 months prior to departure. For country specific incidence rates see the World Health Organization Tuberculosis country profile website <a href="http://www.who.int/tb/country_profiles">World Health Organization TB country Profiles (who.int)</a></i></li> <li><i>Newborn children of migrants who have arrived from countries with a high Tuberculosis incidence in the last 5 years, or newborn children who have close contact with people who have arrived from a high incidence country in the last 5 years.</i></li> <li><i>Newborn children of parents with Leprosy or a family history of Leprosy.</i></li> </ul>

	<ul style="list-style-type: none"> <li>Children less than 6 years of age who have not previously been vaccinated with BCG and are household contacts of newly diagnosed Leprosy.</li> <li>Infant household contacts of Tuberculosis after empiric prophylaxis, if Tuberculin Skin Test (TST) remains negative.</li> </ul>
Patient Exclusion:	<ul style="list-style-type: none"> <li>Any person presenting for vaccination who is assessed by the vaccination provider Registered Nurse as not meeting the patient inclusion criteria</li> <li>Any person with any of the contraindications to receipt of BCG vaccine as listed in the Guidelines for Tuberculosis Control in Western Australia.  <a href="#">Western Australia Tuberculosis Control Program webpage</a></li> </ul> <p>Note: pre-employment BCG vaccination is <u>not</u> an inclusion criteria</p>
Special Instructions:	<p>Ensure completion of the Australian Immunisation Handbook <a href="#">pre- vaccination checklist</a> prior to administration to ensure there are no contraindications to vaccination</p> <p>Seek medical advice before proceeding with BCG vaccination if there are any concerns identified in the pre-vaccination checklist and during the consent process.</p>
Administration Notes:	Standard dosing dependant on age of child to be administered intradermally to the upper arm over the insertion of the deltoid muscle onto the humerus, just above the middle of the upper arm
Clinical Guidelines	<p>See MHPH&amp;DS WATBCP Intradermal BCG Injection Procedure 2023.</p> <p><a href="#">WATBCP Intradermal BCG Injection Procedure</a></p> <p><a href="#">WATBCP Guidelines for TB Control in Western Australia Chapter 6 BCG Vaccination</a></p> <p><a href="#">Australian Immunisation Handbook (on-line) Pre-vaccination checklist</a></p>

<b>Approval</b>			
Date of Issue:	09 December 2024		
Date of Expiry:	09 December 2026		
Clinical Governance Committee			
Committee:	WACHS Medicines and Therapeutics Executive Subcommittee		
Name:	Adam Hort		
Date:	18/12/2024	Signature:	Adam Hort
Senior Medical Practitioner			
Name:	Dr Helen Van Gessel		
Position:	Executive Director Clinical Excellence		
Date:	19/12/2024	Signature:	Helen Van Gessel
A/Chief Executive			
Chairman Name:	John Quinn		
Date:	16/01/2025	Signature:	John Quinn

